Enanta Pharmaceuticals, Inc. ( ENTA) Stock. Should you Buy or Sell? $ 64.04
1.23 (1.88 %)
Enanta Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | ENTA |
| Price | $64.04 |
| Beta | 0.584 |
| Volume Avg. | $246.79 thousand |
| Market Cap | $1.33 B |
| 52 Week Range | $37.59 - $102.0 |
Enanta Pharmaceuticals, Inc. opened the day at $64.04 which is +'1.88 % on yesterday's close. Enanta Pharmaceuticals, Inc. has a 52 week high of $102.0 and 52 week low of $37.59, which is a difference of $64.41. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.33 B and total net profit is $97074000 which means the company is trading at 13.67 times profit to market capitalization. Theoretically, if you were to buy Enanta Pharmaceuticals, Inc. for $1.33 B, it would take 15 years to get your money back. Enanta Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Enanta Pharmaceuticals, Inc. Stock Forecast - Is Enanta Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -11.052 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -1.342 |
Valuing Enanta Pharmaceuticals, Inc.
| Price Book Value Ratio | 3.924 | Price To Book Ratio | 3.924 |
| Price To Sales Ratio | 14.832 | Price Earnings Ratio | -11.052 |
How liquid is Enanta Pharmaceuticals, Inc.
| Current Ratio | 13.590 |
| Quick Ratio | 13.089 |
Debt
| Debt Ratio | 0.123 | Debt Equity Ratio | 0.140 |
| Long Term Debt To Capitalization | 0.062 | Total Debt To Capitalization | 0.068 |
Latest news about Enanta Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration & CFO Tara Kieffer - SVP, New Product Strategy & Development Conference Call Participants Douglas Buchanan - JMP Securities Brian Skorney - Robert W. Baird & Co. Hannah Adeoye - JPMorgan Chase & Co. Roanna Ruiz - SVB Securities Operator Good afternoon, and welcome to Enanta Pharmaceuticals' Fiscal Third Quarter 2022 Financial Results Conference Call.
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June: Jefferies Healthcare Conference: Fireside Chat at 9:00 a.m. ET on June 9, 2022 JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on Ju
About Enanta Pharmaceuticals, Inc.
Description :
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
